Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04019002 · ClinicalTrials.gov registry record · Phase 1
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
A Phase 1 study of Glioblastoma Multiforme (GBM), sponsored by Susan Chang.
- Active
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT04019002: Active Phase 1 study of Glioblastoma Multiforme (GBM), sponsored by Susan Chang.
NCT04019002 is a Phase 1 study of Glioblastoma Multiforme (GBM) that is active but no longer recruiting, run by Susan Chang. The registered enrollment target is 17 participants, below the 69-participant average among 5 other Glioblastoma Multiforme (GBM) trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04019002, a Phase 1 study of Glioblastoma Multiforme (GBM), is active but no longer recruiting, sponsored by Susan Chang.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate whether new metabolic imaging will be useful to physicians and patients with glioblastoma for making treatment decisions and seeing how well various types of treatment work. The goal is to improve the way patient care is managed in the future. If you chose to be in this study, you will be receiving novel magnetic resonance (MR) metabolic imaging with standard MR imaging. The research component includes an injection of an investigational agent, called hyperpolarized 13C pyruvate, to obtain dynamic metabolic imaging.
Primary Outcome
Patients will be monitored for the occurrence of AEs that occur during the course of study participation. AE monitoring occurs on each day of hyperpolarized 13C pyruvate administration and until 7 days after administration. Serious adverse events occurring more than 7 days after administration need only be reported if relationship to the investigational drug is suspected.
Conditions Studied
Interventions
- DRUG Hyperpolarized 13C Pyruvate
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-11-19 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 1 |
What the registry record for NCT04019002 still lists
NCT04019002 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 69-participant average among 5 other Glioblastoma Multiforme (GBM) trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Glioblastoma Multiforme (GBM) appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized 13C Pyruvate is the first listed.
NCT04019002 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04019002 about?
NCT04019002 is a clinical study titled "Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma". The purpose of this study is to evaluate whether new metabolic imaging will be useful to physicians and patients with glioblastoma for making treatment decisions and seeing how well various types of treatment work. The goal is to improve the way patient care is managed in the future. If you chose t...
What is the current status of trial NCT04019002?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2019-11-19. Estimated completion is 2025-09-30.
What conditions does trial NCT04019002 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme (GBM).
What interventions are being tested in trial NCT04019002?
The interventions under investigation include: Hyperpolarized 13C Pyruvate (DRUG).
Who is sponsoring clinical trial NCT04019002?
This trial is sponsored by Susan Chang, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04019002 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme (GBM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RECRUITING · Phase 1
-
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
ACTIVE NOT RECRUITING · Phase 1
-
CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM
COMPLETED · Phase 1
-
Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA
COMPLETED · Phase 1
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI